紫杉醇联合替吉奥与奥沙利铂联合替吉奥在胃癌辅助化疗中的比较研究

doi:10.3969/j.issn.1006-6233.2020.07.025

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1386 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To compare the effect of the combination of paclitaxel and oxaliplatin in the adjuvant chemotherapy of gastric cancer (GC). Methods: 73 patients with advanced GC diagnosed and treated in our hospital from October 2016 to October 2018 were selected as the main subjects. All of them were diagnosed by operation and pathology, and according to the simple random digital table method, divided into the observation group (n=36, chemotherapy of Oxaliposide and Tigiao) and the control group (n =37, chemotherapy of Tigiopaclitaxel and Tigiao).The recent curative effect and the change of the immune function index of the two groups were observed.The overall survival time (OS) of progression-free survival (PFS) was recorded as of October 31,2019, and also the recurrence rate of the two groups and the occurrence of the adverse reactions were recorded. Results: There was no significant difference between the two groups of disease control rate, the postoperative recurrence rate, the PFS and the OS (Pall> 0.05).The levels of Ig A, IgG and IgM after chemotherapy in the two groups were significantly higher than those before chemotherapy(Pall< 0.05).Compared with the control group, the levels of Ig A and IgG in the observation group were significantly higher than those in the control group (Pall< 0.01).The proportion of neutrophils in the observation group was 25.71%, which was significantly lower than that in the control group (48.57%,P < 0.05). Conclusion: The paclitaxel + tigecycline and oxaliplatin + teggio therapies can achieve similar near-term efficacy and survival time. But the oxaliplatin + teggio therapy can improve the immune function of the GC patients and improve the tolerance of the patients, and is worthy of clinical promotion and application.

Key words： Gastric cancer Paclitaxel Oxaliplatin Chemotherapy Tegio Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Chunmei
	ZHOU Guozhi

Cite this article:

WANG Chunmei,ZHOU Guozhi. A Comparative Study of Paclitaxel Combined with Tigiao and Oxaliposide Combined with Tigio in Adjuvant Chemotherapy of Gastric Cancer[J]. HeBei Med, 2020, 26(7): 1160-1164.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.07.025 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I7/1160

[1] 施一鸣,季长风,刘松,等.胃癌不同EGFR表达状态的增强CT表现[J].医学影像学杂志,2019,29(3):425~430.
[2] 刘文静,赵艳秋,胡秀峰,等.紫杉醇脂质体联合替吉奥治疗晚期胃癌的有效性及安全性评价[J].郑州大学学报(医学版),2014,49(6):783~786.
[3] 宁洁,焦洋,李敏,等.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的疗效及安全性研究[J].安徽医药,2017,21(9):1669~1672.
[4] 邹凤双,陈继甫,张艳军.胃癌根治术中吻合器吻合与手法单双层缝合吻合方式的效果比较[J].河北医学,2016,22(8):1352~1355.
[5] 郭萍,张军鹏,贺继东.胃癌患者原发病灶的组织学评价与新辅助化疗预后的相关性[J].国际肿瘤学杂志,2018,45(10):588~592.
[6] 常占国.吉西他滨联合替吉奥治疗晚期胆囊癌的疗效[J].实用临床医学,2018,19(12):18~19.
[7] 莫淼,杨佳柠,董超.阿特珠单抗联合白蛋白结合型紫杉醇治疗晚期三阴性乳腺癌的Ⅲ期临床试验-IMpassion130研究解读[J].中国癌症杂志,2019,29(4):313~320.
[8] 张伟鹏,徐元元,刘苇,等.FOLFOXIRI与SOX化疗方案治疗晚期结直肠癌的近期效果比较[J].肿瘤研究与临床,2018,30(8):548~552.
[9] 沈旭东,庄志祥,甘蕾,等.每周脂质体紫杉醇或奥沙利铂联合替吉奥方案治疗老年晚期胃癌的疗效及安全性分析[J].肿瘤防治研究,2016,43(5):86~89.
[10] 林锦源,杨建伟,高炜,等.胃癌术后氟尿嘧啶联合奥沙利铂或紫杉醇序贯替吉奥方案的临床观察[J].临床肿瘤学杂志,2018,23(6):559~562.
[11] 单永锋,陈艳.替吉奥联合奥沙利铂方案治疗老年胃癌对患者血清肿瘤标志物、基质金属蛋白酶及免疫功能的影响[J].海南医学院学报,2017,23(19):2720~2723.
[12] 王妹兴,肖谜.替吉奥分别联合紫杉醇与奥沙利铂在胃癌术后辅助化疗的应用比较[J].贵州医药,2018,42(3):297~299.